Samsung Biologics' $1.8B PolyPeptide Deal: Peptide & GLP-1 Bet

Samsung Biologics launched an all-cash public tender offer on July 19–20, 2026, to acquire Swiss peptide-API specialist PolyPeptide Group AG for CHF 44.31 per share. The transaction values PolyPeptide's equity at approximately CHF 1.46 billion ($1.8 billion) and represents a 40% premium over PolyPeptide's unaffected CHF 31.65 closing price on April 10, 2026, before takeover rumors surfaced. The tender offer is subject to a 66 2/3% minimum-acceptance threshold, customary regulatory clearances, and standard Swiss takeover board approvals, with closing anticipated toward the end of 2026.

The transaction marks the largest biopharmaceutical acquisition in South Korean corporate history and represents Samsung Biologics' first strategic move into commercial-scale peptide manufacturing. Having built the world's largest monoclonal antibody (mAb) manufacturing footprint (784,000 liters across Plants 1 through 5 in Songdo, South Korea), Samsung Biologics is diversifying beyond recombinant proteins and antibody-drug conjugates (ADCs) into solid-phase peptide synthesis (SPPS). The core commercial driver is the unprecedented global demand for glucagon-like peptide-1 (GLP-1) receptor agonists and multi-incretin therapies. By acquiring PolyPeptide Group—a 70-year-old peptide contract development and manufacturing organization (CDMO) with FY2025 revenues of EUR 389.3 million (+15.6% YoY, driven by a 57% metabolics mix) and six cGMP facilities across Europe, North America, and Asia—Samsung Biologics gains immediate, turn-key peptide API capacity rather than enduring a 3-to-5-year greenfield facility buildout.

This deal follows Samsung Biologics' corporate restructuring on November 3, 2025, when it spun off its biosimilar subsidiary Samsung Bioepis into Samsung Epis Holdings (approved by 99.9% of shareholders) to establish itself as a pure-play CDMO. Combined with the April 2025 commissioning of its 180,000-liter Plant 5 ADC suite and the April 2026 acquisition of a commercial manufacturing facility in Rockville, Maryland, the PolyPeptide deal positions Samsung Biologics to challenge European peptide leaders Bachem, Lonza, and CordenPharma in the rapidly growing $5 billion+ global peptide-CDMO market.

What did Samsung Biologics pay for PolyPeptide and when does the deal close?

The financial architecture of the acquisition relies on an all-cash tender offer for 100% of PolyPeptide Group AG's outstanding registered shares (ticker: PPGN on SIX Swiss Exchange). The offer parameters and transaction mechanics are summarized below:

Samsung Biologics' offer price values PolyPeptide at an enterprise value-to-revenue multiple of approximately 4.0x based on PolyPeptide's FY2025 net revenue of EUR 389.3 million (~CHF 365 million). While high relative to standard small-molecule active pharmaceutical ingredient (API) suppliers, this valuation aligns with recent specialized biopharma CDMO transactions, reflecting the steep technical barriers, specialized equipment leads, and regulatory expertise required for commercial-scale peptide synthesis.

The 66 2/3% minimum-acceptance condition is expected to be met smoothly, as key long-term shareholders holding significant blocks have entered into transaction agreements to tender their shares. Following completion of the tender offer and settlement, Samsung Biologics intends to initiate squeeze-out proceedings under Swiss takeover law to acquire any remaining shares and delist PolyPeptide Group AG from the SIX Swiss Exchange.

Why is a biologic CDMO buying a peptide-API manufacturer?

Samsung Biologics' core business model historically centered on large-scale mammalian cell culture—building massive stainless-steel bioreactors (up to 15,000L and 18,000L vessels) optimized for monoclonal antibodies, recombinant proteins, and, more recently, antibody-drug conjugates. However, the commercial biopharma landscape has shifted dramatically due to the rapid expansion of metabolic disease therapies, peptide therapeutics, and targeted radiopharmaceuticals.

The decision to acquire a synthetic peptide specialist rather than building internal capacity stems from three key operational realities:

1. The Synthetic vs. Recombinant Divide: While early-generation insulins and peptides were produced via recombinant fermentation, modern multi-target incretin analogs (including complex long-acting GLP-1/GIP/Glucagon tri-agonists, non-natural amino acid substitutions, and lipophilic fatty-acid side chains) rely heavily on Solid-Phase Peptide Synthesis (SPPS) or hybrid SPPS/Liquid-Phase Peptide Synthesis (LPPS). Samsung's stainless-steel bioreactors cannot perform SPPS chemistry, which requires specialized chemical reactors, organic solvent handling, specialized cleavage systems, and preparative high-performance liquid chromatography (HPLC).
2. Execution Speed for the GLP-1 Capacity Surge: Global clinical and commercial demand for metabolic disease therapies has outstripped worldwide contract manufacturing capacity. Expanding GLP-1 manufacturing capacity bottlenecks requires multi-year lead times to procure large-scale glass-lined or stainless-steel SPPS reactors, industrial preparative HPLC columns, and explosion-proof (ATEX-certified) manufacturing suites. Building a greenfield commercial SPPS site requires 36 to 48 months from ground-breaking to FDA cGMP validation. Buying PolyPeptide gives Samsung immediate access to fully validated commercial capacity.
3. Cross-Modality Conjugation Opportunities: The biopharma pipeline is increasingly focused on peptide-drug conjugates (PDCs), radiolabeled peptides, and peptide-oligonucleotide hybrids. Pairing Samsung's ADC conjugation capabilities (opened at Plant 5 in April 2025) with PolyPeptide's custom peptide synthesis enables Samsung to offer end-to-end PDC development under a single corporate umbrella.

How big is PolyPeptide and where does it manufacture?

PolyPeptide Group AG is one of the premier global pure-play peptide CDMOs, boasting a 70-year operating heritage tracing back to the early commercial development of peptide hormones in Europe. In its FY2025 financial disclosures (published March 12, 2026), PolyPeptide reported strong revenue recovery and operational acceleration:

• Net Revenue: EUR 389.3 million in FY2025, representing a year-over-year increase of +15.6% (+16.0% in constant currency), driven by surging demand for metabolic disease APIs.
• Metabolics Mix Shift: Metabolic disease applications (including GLP-1, GIP, and glucagon receptor agonists) expanded to account for 57% of total revenue in FY2025, compared to 40% in FY2024 and under 25% in FY2022.
• Profitability Recovery: Rebounded to report an 84% increase in Adjusted EBITDA, supported by improved capacity utilization across European sites and pre-funded customer expansion agreements.
• Capital Expenditures: EUR 110 million invested in FY2025 alone to expand commercial-scale SPPS reactors, automated cleavage systems, and solvent recovery infrastructure. Between 2023 and 2025, PolyPeptide secured EUR 156.2 million in cumulative customer prepayments to reserve future manufacturing capacity.

PolyPeptide operates six integrated cGMP-compliant manufacturing sites across three continents:

                          PolyPeptide Global cGMP Footprint
                                          │
       ┌──────────────────────────────────┼──────────────────────────────────┐
       │                                  │                                  │
[North America]                        [Europe]                           [Asia]
       │                                  │                                  │
 ┌─────┴─────────────┐          ┌─────────┴──────────┐                 ┌─────┴─────────────┐
 │ Torrance, CA (US) │          │ Braine-l'Alleud(BE)│                 │ Ambernath (India) │
 │ San Diego, CA(US) │          │ Malmö (Sweden)     │                 └───────────────────┘
 └───────────────────┘          │ Strasbourg (FR)    │
                                └────────────────────┘

• Braine-l'Alleud, Belgium: The flagship European site, housing large-scale SPPS chemical synthesis, preparative HPLC purification lines, and commercial-scale freeze-drying (lyophilization) suites for metabolic and oncology APIs.
• Malmö, Sweden: Specialized in commercial peptide manufacturing and continuous process development. In September 2025, PolyPeptide completed a major facility extension in Malmö, doubling its local SPPS synthesis capacity with modular multi-thousand-liter reactor trains.
• Strasbourg, France: Dedicated to custom peptide development, early-phase clinical trials supplies, and complex short-chain synthetic sequences.
• Torrance & San Diego, California, USA: Dual U.S. facilities providing cGMP custom synthesis, analytical validation, and commercial API supply for North American sponsors.
• Ambernath, India: Low-cost, high-volume production site optimized for generic peptide APIs, intermediates, and custom raw materials.

Over its multi-decade history, PolyPeptide has manufactured more than 1,000 therapeutic peptide sequences and supported over 30 FDA and EMA commercial drug approvals.

How does this deal fit Samsung Biologics' post-spin-off pure-play CDMO strategy?

The acquisition of PolyPeptide represents the logical execution of Samsung Biologics' corporate restructuring strategy initiated in late 2025.

On November 3, 2025, Samsung Biologics finalized the corporate spin-off of its biosimilar development entity, Samsung Bioepis, transferring Bioepis shares to a newly created holding company, Samsung Epis Holdings. Receiving 99.9% shareholder approval, the transaction removed potential conflict-of-interest concerns for global pharmaceutical clients who were hesitant to contract large-scale manufacturing to a company operating a competing biosimilar commercial organization.

                    Samsung Biologics Evolution (2025–2026)
                                       │
        ┌──────────────────────────────┴──────────────────────────────┐
        │                                                             │
[Nov 3, 2025 Spin-off]                                   [2025-2026 CDMO Expansion]
        │                                                             │
  Samsung Bioepis ──► Samsung Epis Holdings            ┌──────────────┼──────────────┐
  (Biosimilars separated from CDMO core)               │              │              │
                                                   Plant 5        US Site       PolyPeptide
                                                   (Songdo)    (Rockville MD)    (6 Sites)
                                                    180kL ADC    Commercial      $1.8B SPPS
                                                   Apr 2025       Apr 2026      Jul 2026

With the Bioepis separation complete, Samsung Biologics redefined itself strictly as a pure-play CDMO partner. It then executed a rapid series of capacity expansion steps:

• Songdo Plant 5 (April 2025): Operationalized a 180,000-liter facility dedicated to cell culture and dedicated antibody-drug conjugate (ADC) suites, bringing total Songdo bioreactor capacity across Plants 1–5 to 784,000 liters.
• Rockville, Maryland Acquisition (April 2026): Acquired a commercial biomanufacturing facility in the United States, expanding total global mammalian bioreactor capacity toward 845,000 liters while establishing a local U.S. manufacturing hub.
• Financial Performance: Samsung Biologics reported FY2025 revenue of KRW 4,557 billion (~$3.5 billion), marking a +30.3% YoY growth rate. The company guided for FY2026 revenue growth of +15% to +20%, backed by cumulative contract backlogs exceeding $21 billion and holding 420 cumulative global regulatory approvals.

By adding PolyPeptide's six peptide manufacturing facilities to its existing network in South Korea and the United States, Samsung transforms into a multi-modality CDMO giant spanning mAbs, ADCs, mRNA, recombinant proteins, and synthetic peptides. Contextualized within biopharma M&A by the numbers (2026), Samsung's $1.8 billion outlay demonstrates how major CDMOs are deploying balance-sheet strength to secure specialized modality footprints while drug developers focus capital on clinical R&D.

What does the deal mean for GLP-1 manufacturing capacity and the peptide-CDMO competitive landscape?

The global peptide CDMO market is experiencing unprecedented demand, driven by the clinical success of GLP-1 receptor agonists (semaglutide, tirzepatide) and next-generation dual and triple incretin agonists (survodutide, retatrutide, cagrilintide combinations). Industry estimates project the total addressable market for peptide CDMO services to grow from $4.59 billion–$5.52 billion in 2025 to over $12 billion by 2032, expanding at a compound annual growth rate (CAGR) of nearly 20%. Solid-Phase Peptide Synthesis (SPPS) accounts for approximately 58% to 68% of total manufacturing value.

                    Peptide CDMO Market Share & Strategy
                                       │
     ┌─────────────────────────────────┼─────────────────────────────────┐
     │                                 │                                 │
[Bachem Group]                   [Lonza / Corden]                [Samsung / PolyPeptide]
     │                                 │                                 │
 ~22% Market Share               Major Expansion                  Post-Acquisition
 Bubendorf / Sisseln              Corden: $541M Basel              1.8B Scale + 6 Sites
 SPPS Capacity Lead               Lonza: Visp Peptide              Combined mAb + Peptide

Prior to Samsung's acquisition of PolyPeptide, the commercial peptide-CDMO space was dominated by European specialists and tier-one global CDMOs:

• Bachem Group (Switzerland): The historical market leader holding an estimated ~22% global market share in commercial peptide API supply. Bachem has been deploying massive capital expenditure programs at its Bubendorf and Sisseln sites in Switzerland to erect multi-ton SPPS production lines.
• CordenPharma (Germany/Switzerland): Executing a EUR 500 million ($541 million) peptide growth drive—part of a broader $1.08 billion capital allocation plan—to build greenfield peptide synthesis capacity in Basel, Switzerland, and Colorado, USA.
• Lonza Group (Switzerland): Expanding large-scale peptide synthesis suites at its Visp facility while integrating peptide-conjugate technologies into its bioconjugation network.
• AmbioPharm (USA/China): Operating high-volume SPPS lines in South Carolina and Shanghai targeting mid-scale clinical and commercial peptide programs.

Samsung's entry into this segment with $1.8 billion in capital fundamentally alters market dynamics. PolyPeptide possessed deep technical expertise and strong client relationships but faced balance-sheet constraints when competing against multi-billion-dollar capex commitments from Bachem and Lonza. Backed by Samsung Biologics' balance sheet, client network, and procurement scale, PolyPeptide can accelerate its capacity expansions in Malmö, Braine-l'Alleud, and the U.S.

However, operational integration presents real challenges. Operating a multi-site synthetic chemistry footprint across Switzerland, Belgium, Sweden, France, India, and the U.S. requires distinct quality control standards compared to managing centralized bioreactor plants in Songdo. As outlined in our analysis of CDMO quality-agreement red flags and FDA inspection findings, harmonizing cGMP quality management systems, analytical testing procedures, and FDA 483 response protocols across cross-border acquisitions is critical to avoiding batch releases or regulatory holds.

Furthermore, unlike transactions where a pharmaceutical sponsor acquires a single-asset drug candidate with a defined patent runway—such as Neurocrine's $2.9 billion Soleno acquisition, Samsung's purchase of PolyPeptide is a pure capacity and service-platform acquisition. PolyPeptide owns no proprietary drug patents or branded therapeutics; its commercial success depends entirely on executing contract manufacturing agreements, maintaining regulatory compliance, and retaining key peptide chemistry talent.

If Samsung successfully completes the tender offer and integrates PolyPeptide by late 2026, it will create a true multi-modality contract manufacturer capable of supplying everything from 20,000L bioreactor mAb runs to multi-kilogram synthetic GLP-1 peptide APIs under one global banner.

Sources

• U.S. Food and Drug Administration (FDA) Drugs@FDA Database: FDA Approval Records and Active Ingredient Registrations for GLP-1 Receptor Agonists (Semaglutide, Tirzepatide), Reference Listed Drug Records. Available at: Drugs@FDA
• Samsung Biologics Company Disclosures: Samsung Biologics Announces All-Cash Offer to Acquire PolyPeptide, Press Release (July 19, 2026). Available at: PRNewswire
• PolyPeptide Group AG Investor Relations: PolyPeptide Group FY 2025 Financial Results & Media Release, SIX Swiss Exchange Ad-Hoc Announcement (March 12, 2026). Available at: PolyPeptide Group
• Samsung Biologics Corporate Restructuring: Samsung Biologics Completes Spin-off to Strengthen Its Focus as a Pure-Play CDMO, Corporate News (November 3, 2025). Available at: Samsung Biologics IR
• Samsung Biologics Financial Earnings: Fourth Quarter and Fiscal Year 2025 Financial Results, Financial Report (January 23, 2026). Available at: Samsung Biologics IR
• Chemical & Engineering News (C&EN): Samsung makes a $1.8 billion bet on peptide production, Business M&A Report (July 2026). Available at: C&EN ACS
• CNBC Financial Reporting: Samsung Biologics to buy Swiss PolyPeptide Group in $1.8 billion deal, European Business News (July 20, 2026). Available at: CNBC